[Antihyperglycemic treatment guidelines for diabetes mellitus type 2 (Update 2023)].
Antihyperglykämische Therapie bei Diabetes mellitus Typ 2 (Update 2023).
Diabetes mellitus Type 2
Therapy Glucose lowering
Journal
Wiener klinische Wochenschrift
ISSN: 1613-7671
Titre abrégé: Wien Klin Wochenschr
Pays: Austria
ID NLM: 21620870R
Informations de publication
Date de publication:
Jan 2023
Jan 2023
Historique:
accepted:
01
03
2023
medline:
28
4
2023
pubmed:
27
4
2023
entrez:
26
4
2023
Statut:
ppublish
Résumé
Hyperglycemia significantly contributes to complications in patients with diabetes mellitus. While lifestyle interventions remain cornerstones of disease prevention and treatment, most patients with type 2 diabetes will eventually require pharmacotherapy for glycemic control. The definition of individual targets regarding optimal therapeutic efficacy and safety as well as cardiovascular effects is of great importance. In this guideline we present the most current evidence-based best clinical practice data for healthcare professionals. Die Hyperglykämie ist wesentlich an der Entstehung der Spätkomplikationen bei an Diabetes mellitus Typ 2 erkrankten Patienten/Patientinnen beteiligt. Während Lebensstilmaßnahmen die Eckpfeiler jeder Diabetestherapie bleiben, benötigen im Verlauf die meisten Patienten/Patientinnen mit Typ 2 Diabetes eine medikamentöse Therapie. Bei der Definition individueller Behandlungsziele stellen die Therapiesicherheit, die Effektivität sowie substanzspezifische, kardiovaskuläre Effekte der Therapie die wichtigsten Faktoren dar. In dieser Leitlinie haben wir die rezenten evidenzbasierten Daten für die klinische Praxis zusammengestellt.
Autres résumés
Type: Publisher
(ger)
Die Hyperglykämie ist wesentlich an der Entstehung der Spätkomplikationen bei an Diabetes mellitus Typ 2 erkrankten Patienten/Patientinnen beteiligt. Während Lebensstilmaßnahmen die Eckpfeiler jeder Diabetestherapie bleiben, benötigen im Verlauf die meisten Patienten/Patientinnen mit Typ 2 Diabetes eine medikamentöse Therapie. Bei der Definition individueller Behandlungsziele stellen die Therapiesicherheit, die Effektivität sowie substanzspezifische, kardiovaskuläre Effekte der Therapie die wichtigsten Faktoren dar. In dieser Leitlinie haben wir die rezenten evidenzbasierten Daten für die klinische Praxis zusammengestellt.
Identifiants
pubmed: 37101023
doi: 10.1007/s00508-023-02186-4
pii: 10.1007/s00508-023-02186-4
pmc: PMC10133357
doi:
Substances chimiques
Hypoglycemic Agents
0
Blood Glucose
0
Types de publication
English Abstract
Journal Article
Langues
ger
Sous-ensembles de citation
IM
Pagination
32-44Informations de copyright
© 2023. The Author(s).
Références
Bhatt DL, et al. Sotagliflozin in patients with diabetes and recent worsening heart failure. N Engl J Med. 2021;384(2):117–28.
doi: 10.1056/NEJMoa2030183
pubmed: 33200892
Bhatt DL, et al. Sotagliflozin in patients with diabetes and chronic kidney disease. N Engl J Med. 2021;384(2):129–39.
doi: 10.1056/NEJMoa2030186
pubmed: 33200891
Ludvik B, et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. Lancet. 2021;398(10300):583–98.
doi: 10.1016/S0140-6736(21)01443-4
pubmed: 34370970
Holman RR, et al. Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2017;5(11):877–86.
doi: 10.1016/S2213-8587(17)30309-1
pubmed: 28917545
UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352(9131):837–53.
doi: 10.1016/S0140-6736(98)07019-6
Holman RR, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359(15):1577–89.
doi: 10.1056/NEJMoa0806470
pubmed: 18784090
Group AC, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358(24):2560–72.
doi: 10.1056/NEJMoa0802987
Action to Control Cardiovascular Risk in Diabetes Study G, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358(24):2545–59.
doi: 10.1056/NEJMoa0802743
Duckworth W, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360(2):129–39.
doi: 10.1056/NEJMoa0808431
pubmed: 19092145
Ferrannini E, DeFronzo RA. Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes. Eur Heart J. 2015;36(34):2288–96.
doi: 10.1093/eurheartj/ehv239
pubmed: 26063450
Zinman B, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117–28.
doi: 10.1056/NEJMoa1504720
pubmed: 26378978
Wiviott SD, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380(4):347–57.
doi: 10.1056/NEJMoa1812389
pubmed: 30415602
Neal B, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644–57.
doi: 10.1056/NEJMoa1611925
pubmed: 28605608
Cannon CP, et al. Cardiovascular outcomes with ertugliflozin in type 2 diabetes. N Engl J Med. 2020;383(15):1425–35.
doi: 10.1056/NEJMoa2004967
pubmed: 32966714
Marso SP, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311–22.
doi: 10.1056/NEJMoa1603827
pubmed: 27295427
pmcid: 4985288
Gerstein HC, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019;394(10193):121–30.
doi: 10.1016/S0140-6736(19)31149-3
pubmed: 31189511
Marso SP, Holst AG, Vilsboll T. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2017;376(9):891–2.
pubmed: 28249135
Husain M, et al. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2019;381(9):841–51.
doi: 10.1056/NEJMoa1901118
pubmed: 31185157
Dormandy JA, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005;366(9493):1279–89.
doi: 10.1016/S0140-6736(05)67528-9
pubmed: 16214598
Erdmann E, et al. The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) study. J Am Coll Cardiol. 2007;49(17):1772–80.
doi: 10.1016/j.jacc.2006.12.048
pubmed: 17466227
Wilcox R, et al. Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: results from PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events 04). Stroke. 2007;38(3):865–73.
doi: 10.1161/01.STR.0000257974.06317.49
pubmed: 17290029
Lincoff AM, et al. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA. 2007;298(10):1180–8.
doi: 10.1001/jama.298.10.1180
pubmed: 17848652
Kernan WN, et al. Pioglitazone after Ischemic stroke or transient Ischemic attack. N Engl J Med. 2016;374(14):1321–31.
doi: 10.1056/NEJMoa1506930
pubmed: 26886418
pmcid: 4887756
Investigators OT, et al. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med. 2012;367(4):319–28.
doi: 10.1056/NEJMoa1203858
Marso SP, Buse JB. Safety of degludec versus glargine in type 2 diabetes. N Engl J Med. 2017;377(20):1995–6.
pubmed: 29141162
McMurray JJV, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995–2008.
doi: 10.1056/NEJMoa1911303
pubmed: 31535829
Packer M, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383(15):1413–24.
doi: 10.1056/NEJMoa2022190
pubmed: 32865377
Anker SD, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021. https://doi.org/10.1056/NEJMoa2107038
doi: 10.1056/NEJMoa2107038
pubmed: 34449189
Solomon SD, et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2022. https://doi.org/10.1056/NEJMoa2206286
doi: 10.1056/NEJMoa2206286
pubmed: 36577112
Perkovic V, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295–306.
doi: 10.1056/NEJMoa1811744
pubmed: 30990260
Heerspink HJL, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383(15):1436–46.
doi: 10.1056/NEJMoa2024816
pubmed: 32970396
The EMPA-KIDNEY Collaborative Group. Empagliflozin in patients with chronic kidney disease. N Engl J Med. 2022; https://doi.org/10.1056/NEJMoa2204233 .
doi: 10.1056/NEJMoa2204233
pmcid: 7614055